Cytori Therapeutics Inc (CYTX)

1.55
0.00 (0.00)
NASDAQ : Health Care
Prev Close 1.55
Open 1.56
Day Low/High 1.53 / 1.57
52 Wk Low/High 1.91 / 7.93
Volume 48.27K
Avg Volume 97.90K
Exchange NASDAQ
Shares Outstanding 20.50M
Market Cap 31.78M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytori Strengthens Global Intellectual Property Portfolio With Key Patents

Cytori Strengthens Global Intellectual Property Portfolio With Key Patents

Cytori Therapeutics, Inc. (NASDAQ: CYTX) ("Cytori" or the "Company") announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.

Cytori Granted FDA Orphan Drug Designation For ECCS-50 In Scleroderma

Cytori Granted FDA Orphan Drug Designation For ECCS-50 In Scleroderma

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for cryopreserved or centrally processed ECCS-50 for...

Cytori Reports Third Quarter 2016 Business And Financial Results

Cytori Reports Third Quarter 2016 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its third quarter financial results and provided updates on its corporate activity and clinical development.

Cytori To Present Data In Two Distinct Models Of Impaired Wound Healing

Cytori To Present Data In Two Distinct Models Of Impaired Wound Healing

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present new preclinical data describing positive effects of Cytori Cell Therapy™ on a corneal wound healing model and in cutaneous scarring following burn injury.

Cytori To Webcast Third Quarter Financial Results On November 9

Cytori To Webcast Third Quarter Financial Results On November 9

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 9, 2016 at 5:30 PM Eastern Time.

Cytori Presents Scleroderma Clinical Trial Data At The 2016 American College Of Rheumatology Annual Meeting

Cytori Presents Scleroderma Clinical Trial Data At The 2016 American College Of Rheumatology Annual Meeting

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present data from its STAR Phase 3 clinical trial describing progress, preliminary blinded patient characteristics, and safety of adipose-derived regenerative cells...

Cytori Publication On Cytori Cell Therapy For Combined Radiation And Thermal Injury

Cytori Publication On Cytori Cell Therapy For Combined Radiation And Thermal Injury

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication of preclinical safety and efficacy study data using Cytori Cell Therapy™ for combined radiation and thermal injury.

BARDA Increases Contract Option With Cytori To Advance Countermeasure Clinical Trial

BARDA Increases Contract Option With Cytori To Advance Countermeasure Clinical Trial

Cytori Therapeutics (NASDAQ: CYTX) (the "Company") today announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.

Cytori To Present In Investor Events In September 2016

Cytori To Present In Investor Events In September 2016

Cytori Therapeutics, Inc. (NASDAQ: CYTX), a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, announced today that management will...

Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award

Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award

Cytori Therapeutics, Inc. (NASDAQ: CYTX) ("Cytori" or the "Company") today announced that it has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of...

Cytori Therapeutics Announced Inducement Grant For New Employee

Cytori Therapeutics Announced Inducement Grant For New Employee

Cytori Therapeutics, Inc. (NASDAQ:CYTX), a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, announced today that the Compensation...

Cytori Reports Second Quarter 2016 Business And Financial Results

Cytori Reports Second Quarter 2016 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its second quarter financial results and provided updates on its corporate activity and clinical development.

Cytori To Webcast Second Quarter Financial Results On August 4

Cytori To Webcast Second Quarter Financial Results On August 4

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Thursday, August 4, 2016 at 5:30 PM Eastern Time.

Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration

Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication of the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to...

Cytori ATHENA Trial For Chronic Ischemic Cardiovascular Disease

Cytori ATHENA Trial For Chronic Ischemic Cardiovascular Disease

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the results from the ATHENA Trials have been published and are now available online in Catheterization and Cardiovascular Interventions, a leading...

Cytori Cell Therapy Receives Limited Approval For Osteoarthritis In Japan

Cytori Cell Therapy Receives Limited Approval For Osteoarthritis In Japan

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the use of Cytori Cell Therapy™ was approved for clinical use on June 24 th, 2016 to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic...

Cytori Closes Rights Offering For Gross Proceeds Of $17.1 Million

Cytori Closes Rights Offering For Gross Proceeds Of $17.1 Million

Cytori Therapeutics, Inc. ("Cytori" or the "Company") (NASDAQ: CYTX) announced today the closing of its rights offering ("Rights Offering") to subscribe for units at a subscription price of $2.

Cytori Announces Expiration Of Rights Offering And Estimated Gross Proceeds Of $17.1 Million

Cytori Announces Expiration Of Rights Offering And Estimated Gross Proceeds Of $17.1 Million

Cytori Therapeutics, Inc. ("Cytori" or the "Company") (NASDAQ: CYTX) announced today that the subscription period for its previously announced rights offering (the "offering") of units at a subscription price of $2.

Cytori Cell Therapy™ Leads To Improved Function And Reduced Scar Tissue In A Urinary Injury Model

Cytori Cell Therapy™ Leads To Improved Function And Reduced Scar Tissue In A Urinary Injury Model

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori Cell Therapy in a large...

Presentation Of Twelve Month Pilot Trial Data Of Cytori® Cell Therapy™ For ACL Reconstruction

Presentation Of Twelve Month Pilot Trial Data Of Cytori® Cell Therapy™ For ACL Reconstruction

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today Dr.

Cytori Announces Enrollment Completion In U.S. Phase III Scleroderma Trial

Cytori Announces Enrollment Completion In U.S. Phase III Scleroderma Trial

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced completion of enrollment for its U.

Cytori Extends Rights Offering Subscription Period To Friday, June 10, And Adjusts Unit Pricing

Cytori Extends Rights Offering Subscription Period To Friday, June 10, And Adjusts Unit Pricing

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has extended the subscription period and adjusted the subscription price for its previously announced rights offering until 5:00 PM Eastern Time on Friday,...

Cytori Announces Commencement Of Subscription Period For Previously Announced Rights Offering

Cytori Announces Commencement Of Subscription Period For Previously Announced Rights Offering

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares of common stock and warrants...

Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial

Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.

Cytori Informs Stockholders Of Key Dates Related To Announced Rights Offering

Cytori Informs Stockholders Of Key Dates Related To Announced Rights Offering

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an informational update to stockholders regarding its recent rights offering and the key dates relative to the offering.

European Scleroderma Trial Investigating Cytori Cell Therapy To Be Presented In Japan

European Scleroderma Trial Investigating Cytori Cell Therapy To Be Presented In Japan

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use of Cytori Cell Therapy in the treatment of...

Cytori Reports First Quarter 2016 Business And Financial Results

Cytori Reports First Quarter 2016 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its first quarter financial results and provided updates on its corporate activity and clinical development.